'We recently launched Yesintek in the immunology space.'
'API prices are dragging down margins and impacting our competitive ability.'
Indian firm to soon launch copycat of anti-breast-cancer drug.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances